The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems

Luyao Wang, Yurong Chen, Xinrui Liu, Ziyi Li, Xiangpeng DaiFrontiers in Oncology 2022 · DOI

TL;DR

This review explores how CRISPR/Cas9 is transforming cancer immunotherapy by enabling precise, high-throughput genetic modifications. From creating "universal" off-the-shelf CAR-T cells to engineering more effective oncolytic viruses, CRISPR is helping researchers overcome treatment resistance and safety hurdles, though significant challenges like off-target effects remain.

What Problem Does This Paper Address?

While immunotherapy has revolutionized oncology, it isn't a silver bullet. Many patients fail to respond due to complex resistance mechanisms, and current treatments like CAR-T cell therapy are often prohibitively expensive and difficult to manufacture because they require a patient’s own cells. Furthermore, traditional methods for engineering viral therapies or identifying drug-resistance genes are slow, multi-step, and inefficient.

The authors summarize how CRISPR/Cas9—a versatile "molecular scissor"—is being used to bridge these gaps by streamlining the development of more potent, scalable, and personalized cancer treatments.

Methods

As a "Mini Review," this paper synthesizes recent advancements rather than introducing a single new experiment. It categorizes the application of CRISPR/Cas9 into several key technical domains:

  • Gene Disruption (NHEJ): Using Non-Homologous End Joining to "knock out" inhibitory genes (like PD-1) in immune cells.
  • Gene Insertion (HDR): Using Homology-Directed Repair to precisely insert therapeutic genes (like CAR receptors) into specific genomic loci.
  • High-Throughput Screening: Utilizing genome-wide CRISPR libraries (containing over 100,000 guide RNAs) to systematically identify which genes, when lost, make cancer cells more vulnerable to the immune system.
  • Multiplex Editing: Simultaneously editing multiple genes to create "universal" donor cells.

Datasets

The paper references several landmark studies and their associated screening tools:

  • 2CT CRISPR Assay: A "two cell-type" assay used to identify essential genes for T-cell effector function.
  • Genome-scale CRISPR/Cas9 Libraries: Mention of libraries containing ~123,000 single-guide RNAs (sgRNAs) used to profile immunotherapy resistance in melanoma and other cancers.
  • Clinical Trial Data: Summaries of phase I/II trials for oncolytic viruses (like T-VEC) and CAR-T therapies.

Key Insights and Ideas

  • The "Universal" CAR-T Cell: One of the most exciting prospects is using CRISPR to knock out the endogenous T-cell receptor (TCR) and the HLA-I molecule (via the B2M gene). This prevents Graft-versus-Host Disease (GVHD), potentially allowing for "off-the-shelf" cell products that can be used for any patient.
  • Overcoming the "Don't Eat Me" Signal: Cancer cells often express CD47 to tell macrophages not to eat them. CRISPR is being used to knock out the corresponding receptor (SIRP-$\alpha$) on macrophages, effectively "unmasking" the cancer cells for destruction.
  • Viral Engineering Efficiency: Traditional adenovirus engineering is notoriously tedious. CRISPR has shown the ability to increase the efficiency of homologous recombination in viral genomes from near-zero (0.0000015%) to over 8%, a massive leap for manufacturing oncolytic viruses.
  • Fighting T-Cell Exhaustion: By knocking out inhibitory receptors like PD-1, LAG3, or the E3 ubiquitin ligase Cbl-b, researchers can create "armored" T cells that remain active longer within the harsh, immunosuppressive environment of a tumor.

Key Results

  • Clinical Remission: The review highlights that CD19-specific CAR-T therapies have achieved up to 90% complete remission in acute lymphoblastic leukemia (ALL).
  • NK Cell Optimization: CRISPR-mediated knockout of the CD38 gene in Natural Killer (NK) cells reduced "fratricide" (NK cells killing each other) during expansion, leading to more effective AML targeting.
  • Novel Target Discovery: High-throughput screens identified FAM49B as a novel regulator of T-cell activation, providing a new target for future drug development.

Limitations and Future Work

Despite the promise, the authors identify several "red flags" that require further research:

  • Off-Target Effects: Cas9 can sometimes cut DNA at unintended sites, potentially disabling tumor-suppressor genes or activating oncogenes.
  • The p53 Problem: Recent studies suggest that the DNA breaks caused by CRISPR can trigger a p53-mediated damage response, which might inadvertently select for p53-deficient cells (which are more prone to becoming cancerous).
  • Chromosomal Translocations: When making multiple edits simultaneously (multiplexing), there is a risk of large-scale genomic rearrangements.
  • Future Directions: The authors point toward the development of high-fidelity Cas9 variants (like SpCas9-HF1) and truncated sgRNAs (17 nucleotides instead of 20) to increase specificity and reduce the risks of this powerful technology.

Summary updated

Abstract

Cancer is one of the main causes of disease-related deaths in the world. Although cancer treatment strategies have been improved in recent years, the survival time of cancer patients is still far from satisfied. Cancer immunotherapy, such as Oncolytic virotherapy, Immune checkpoints inhibition, Chimeric antigen receptor T (CAR-T) cell therapy, Chimeric antigen receptor natural killer (CAR-NK) cell therapy and macrophages genomic modification, has emerged as an effective therapeutic strategy for different kinds of cancer. However, many patients do not respond to the cancer immunotherapy which warrants further investigation to optimize this strategy. The clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9 (CRISPR/Cas9), as a versatile genome engineering tool, has become popular in the biology research field and it was also applied to optimize tumor immunotherapy. Moreover, CRISPR-based high-throughput screening can be used in the study of immunomodulatory drug resistance mechanism. In this review, we summarized the development as well as the application of CRISPR/Cas9 technology in the cancer immunotherapy and discussed the potential problems that may be caused by this combination.
BibTeX
@inproceedings{wang2022application,
  author = {Luyao Wang and Yurong Chen and Xinrui Liu and Ziyi Li and Xiangpeng Dai},
  title = {{The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems}},
  booktitle = {Frontiers in Oncology},
  year = {2022},
  doi = {10.3389/fonc.2021.704999},
}
Figure